Development of an Interferon Gamma Response-Related Signature for Prediction of Survival in Clear Cell Renal Cell Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Baldewijns MM, van Vlodrop IJ, Schouten LJ, Soetekouw PM, de Bruine AP, van Engeland M. Genetics and epigenetics of renal cell cancer. Biochim Biophys Acta. 2008;1785:133–155.
   PubMed Web of Science ®Google Scholar
• Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM, The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105. doi:10.1016/j.eururo.2016.02.029
   PubMed Web of Science ®Google Scholar
• Sondka Z, Bamford S, Cole CG, Ward SA, Dunham I, Forbes SA, The COSMIC cancer gene census: describing genetic dysfunction across all human cancers. Nat Rev Cancer. 2018;18(11):696–705. doi:10.1038/s41568-018-0060-1
   PubMed Web of Science ®Google Scholar
• Abril E, Mendez RE, Garcia A, et al. Characterization of a gastric tumor cell line defective in MHC class I inducibility by both alpha- and gamma-interferon. Tissue Antigens. 1996;47(5):391–398.
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA, Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Allavena P, Sica A, Solinas G, Porta C, Mantovani A, The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol. 2008;66(1):1–9. doi:10.1016/j.critrevonc.2007.07.004
   PubMed Web of Science ®Google Scholar
• Chan G, Kalaitzidis D, Neel BG, The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 2008;27(2):179–192. doi:10.1007/s10555-008-9126-y
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD, Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991–998. doi:10.1038/ni1102-991
   PubMed Web of Science ®Google Scholar
• Beatty GL, Gladney WL, Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21(4):687–692. doi:10.1158/1078-0432.CCR-14-1860
   PubMed Web of Science ®Google Scholar
• Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51–81.
   PubMed Web of Science ®Google Scholar
• Lambert AW, Pattabiraman DR, Weinberg RA, Emerging biological principles of metastasis. Cell. 2017;168(4):670–691. doi:10.1016/j.cell.2016.11.037
   PubMed Web of Science ®Google Scholar
• Folkman J, Merler E, Abernathy C, Williams G, Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971;133(2):275–288. doi:10.1084/jem.133.2.275
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J, Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86(3):353–364. doi:10.1016/S0092-8674(00)80108-7
   PubMed Web of Science ®Google Scholar
• Xu WH, Xu Y, Wang J, et al. Prognostic value and immune infiltration of novel signatures in clear cell renal cell carcinoma microenvironment. Aging (Albany NY). 2019;11(17):6999–7020.
   PubMedGoogle Scholar
• Linehan WM, Schmidt LS, Crooks DR, et al. The metabolic basis of kidney cancer. Cancer Discov. 2019;9(8):1006–1021.
   PubMed Web of Science ®Google Scholar
• Kursunel MA, Esendagli G. The untold story of IFN-gamma in cancer biology. Cytokine Growth Factor Rev. 2016;31:73–81. doi:10.1016/j.cytogfr.2016.07.005
   PubMed Web of Science ®Google Scholar
• Castro F, Cardoso AP, Goncalves RM, Serre K, Oliveira MJ. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol. 2018;9:847.
   PubMed Web of Science ®Google Scholar
• Maraskovsky E, Chen WF, Shortman K. IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J Immunol. 1989;143:1210–1214.
   PubMed Web of Science ®Google Scholar
• Curtsinger JM, Agarwal P, Lins DC, Mescher MF, Autocrine IFN-gamma promotes naive CD8 T cell differentiation and synergizes with IFN-alpha to stimulate strong function. J Immunol. 2012;189(2):659–668. doi:10.4049/jimmunol.1102727
   PubMed Web of Science ®Google Scholar
• Haabeth OA, Lorvik KB, Hammarstrom C, et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun. 2011;2(1):240.
   PubMedGoogle Scholar
• Nathan CF, Murray HW, Wiebe ME, Rubin BY, Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med. 1983;158(3):670–689. doi:10.1084/jem.158.3.670
   PubMed Web of Science ®Google Scholar
• Corthay A, Skovseth DK, Lundin KU, et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity. 2005;22(3):371–383.
   PubMed Web of Science ®Google Scholar
• Akbar SM, Inaba K, Onji M, Upregulation of MHC class II antigen on dendritic cells from hepatitis B virus transgenic mice by interferon-gamma: abrogation of immune response defect to a T-cell-dependent antigen. Immunology. 1996;87(4):519–527. doi:10.1046/j.1365-2567.1996.516576.x
   PubMed Web of Science ®Google Scholar
• Walter W, Lingnau K, Schmitt E, Loos M, Maeurer MJ, MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? Br J Cancer. 2000;83(9):1192–1201. doi:10.1054/bjoc.2000.1415
   PubMed Web of Science ®Google Scholar
• Subramaniam PS, Torres BA, Johnson HM, So many ligands, so few transcription factors: a new paradigm for signaling through the STAT transcription factors. Cytokine. 2001;15(4):175–187. doi:10.1006/cyto.2001.0905
   PubMed Web of Science ®Google Scholar
• de Veer MJ, Holko M, Frevel M, et al., Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol. 2001;69:912–920.
   PubMed Web of Science ®Google Scholar
• Yao B, Wang L, Wang H, et al. Seven interferon gamma response genes serve as a prognostic risk signature that correlates with immune infiltration in lung adenocarcinoma. Aging (Albany NY). 2021;13(8):11381–11410.
   PubMedGoogle Scholar
• Ma J, Cai X, Kang L, Chen S, Liu H, Identification of novel biomarkers and candidate small-molecule drugs in cutaneous melanoma by comprehensive gene microarrays analysis. J Cancer. 2021;12(5):1307–1317. doi:10.7150/jca.49702
   PubMed Web of Science ®Google Scholar
• Geeleher P, Cox N, Huang RS, Barbour JD, pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One. 2014;9(9):e107468. doi:10.1371/journal.pone.0107468
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–262.
   PubMed Web of Science ®Google Scholar
• Reddy GK, Bukowski RM, Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma. Clin Genitourin Cancer. 2006;4(4):246–248. doi:10.3816/CGC.2006.n.002
   PubMed Web of Science ®Google Scholar
• Schmid TA, Gore ME, Sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol. 2016;8(6):348–371. doi:10.1177/1756287216663979
   PubMedGoogle Scholar
• Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind Phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013;49(6):1287–1296.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–124.
   PubMed Web of Science ®Google Scholar
• Hutson TE, Lesovoy V, Al-Shukri S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label Phase 3 trial. Lancet Oncol. 2013;14(13):1287–1294.
   PubMed Web of Science ®Google Scholar
• Tung I, Sahu A. Immune checkpoint inhibitor in first-line treatment of metastatic renal cell carcinoma: a review of current evidence and future directions. Front Oncol. 2021;11:707214. doi:10.3389/fonc.2021.707214
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–1115.
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127.
   PubMed Web of Science ®Google Scholar
• Daugan MV, Revel M, Russick J, et al. Complement C1s and C4d as prognostic biomarkers in renal cancer: emergence of noncanonical functions of C1s. Cancer Immunol Res. 2021;9(8):891–908.
   PubMed Web of Science ®Google Scholar
• Huang WC, Tung SL, Chen YL, Chen PM, Chu PY, IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway. BMC Cancer. 2018;18(1):609. doi:10.1186/s12885-018-4529-9
   PubMedGoogle Scholar
• Wang Y, Chen Y, Zhu B, Ma L, Xing Q. A novel nine apoptosis-related genes signature predicting overall survival for kidney renal clear cell carcinoma and its associations with immune infiltration. Front Mol Biosci. 2021;8:567730. doi:10.3389/fmolb.2021.567730
   PubMed Web of Science ®Google Scholar
• Pan H, Wang X, Huang W, et al. Interferon-induced protein 44 correlated with immune infiltration serves as a potential prognostic indicator in head and neck squamous cell carcinoma. Front Oncol. 2020;10:557157. doi:10.3389/fonc.2020.557157
   PubMed Web of Science ®Google Scholar
• Wisdom AJ, Hong CS, Lin AJ, et al. Neutrophils promote tumor resistance to radiation therapy. Proc Natl Acad Sci U S A. 2019;116(37):18584–18589.
   PubMed Web of Science ®Google Scholar
• Ma H, Zhou H, Song X, Shi S, Zhang J, Jia L, Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia. Oncogene. 2015;34(6):726–740. doi:10.1038/onc.2014.7
   PubMed Web of Science ®Google Scholar
• Mondal S, Chandra S, Mandal C, Elevated mRNA level of hST6Gal I and hST3Gal V positively correlates with the high risk of pediatric acute leukemia. Leuk Res. 2010;34(4):463–470. doi:10.1016/j.leukres.2009.07.042
   PubMed Web of Science ®Google Scholar
• Ouyang X, Hao X, Liu S, Hu J, Hu L, Expression of Nup93 is associated with the proliferation, migration and invasion capacity of cervical cancer cells. Acta Biochim Biophys Sin. 2019;51(12):1276–1285. doi:10.1093/abbs/gmz131
   Google Scholar
• Bersini S, Lytle NK, Schulte R, Huang L, Wahl GM, Hetzer MW, Nup93 regulates breast tumor growth by modulating cell proliferation and actin cytoskeleton remodeling. Life Sci Alliance. 2020;3(1):e201900623. doi:10.26508/lsa.201900623
   PubMed Web of Science ®Google Scholar
• Oshiumi H, Miyashita M, Okamoto M, et al. DDX60 is involved in RIG-I-dependent and independent antiviral responses, and its function is attenuated by virus-induced EGFR activation. Cell Rep. 2015;11(8):1193–1207.
   PubMed Web of Science ®Google Scholar
• Xin D, Liu J, Gu J, et al. Low expression of DDX60 gene might associate with the radiosensitivity for patients with breast cancer. J Oncol. 2020;2020:8309492. doi:10.1155/2020/8309492
   PubMed Web of Science ®Google Scholar
• Pan Y, Wu Y, Hu J, et al. Long noncoding RNA HOTAIR promotes renal cell carcinoma malignancy through alpha-2, 8-sialyltransferase 4 by sponging microRNA-124. Cell Prolif. 2018;51(6):e12507.
   PubMed Web of Science ®Google Scholar
• Ma W, Zhao X, Liang L, et al. miR-146a and miR-146b promote proliferation, migration and invasion of follicular thyroid carcinoma via inhibition of ST8SIA4. Oncotarget. 2017;8(17):28028–28041.
   PubMedGoogle Scholar
• Ito A, Mimae T, Yamamoto YS, et al. Novel application for pseudopodia proteomics using excimer laser ablation and two-dimensional difference gel electrophoresis. Lab Invest. 2012;92(9):1374–1385.
   PubMed Web of Science ®Google Scholar
• Fan X, Liu L, Shi Y, et al. Integrated analysis of RNA-binding proteins in human colorectal cancer. World J Surg Oncol. 2020;18(1):222.
   PubMed Web of Science ®Google Scholar
• Kaneda MM, Messer KS, Ralainirina N, et al. PI3Kgamma is a molecular switch that controls immune suppression. Nature. 2016;539(7629):437–442.
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Quiceno DG, Ochoa AC, L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood. 2007;109(4):1568–1573. doi:10.1182/blood-2006-06-031856
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S, Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother. 2010;59(10):1593–1600. doi:10.1007/s00262-010-0855-8
   PubMed Web of Science ®Google Scholar
• Schlecker E, Stojanovic A, Eisen C, et al. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol. 2012;189(12):5602–5611.
   PubMed Web of Science ®Google Scholar
• Terabe M, Swann J, Ambrosino E, et al. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med. 2005;202(12):1627–1633.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Martin F, Zitvogel L, The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev. 2006;214(1):229–238. doi:10.1111/j.1600-065X.2006.00445.x
   PubMedGoogle Scholar
• Ryba M, Mysliwska J. CD4+CD25+Foxp3+ T lymphocytes: naturally occurring regulatory T cells. Pediatr Endocrinol Diabetes Metab. 2010;16:289–294.
   PubMedGoogle Scholar
• Zhdanov DD, Gladilina YA, Pokrovsky VS, et al. Murine regulatory T cells induce death of effector T, B, and NK lymphocytes through a contact-independent mechanism involving telomerase suppression and telomere-associated senescence. Cell Immunol. 2018;331:146–160. doi:10.1016/j.cellimm.2018.06.008
   PubMed Web of Science ®Google Scholar
• Zhdanov DD, Gladilina YA, Grishin DV, et al. Contact-independent suppressive activity of regulatory T cells is associated with telomerase inhibition, telomere shortening and target lymphocyte apoptosis. Mol Immunol. 2018;101:229–244. doi:10.1016/j.molimm.2018.07.017
   PubMed Web of Science ®Google Scholar
• Molina AM, Motzer RJ, Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist. 2011;16(Suppl S2):45–50. doi:10.1634/theoncologist.2011-S2-45
   PubMedGoogle Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27(20):3312–3318.
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–134.
   PubMed Web of Science ®Google Scholar
• Pena C, Lathia C, Shan M, Escudier B, Bukowski RM, Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in renal cancer global evaluation trial. Clin Cancer Res. 2010;16(19):4853–4863. doi:10.1158/1078-0432.CCR-09-3343
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–1068.
   PubMed Web of Science ®Google Scholar
• Geczi L, Bodoky G, Rokszin G, Fabian I, Torday L, Survival benefits of second-line axitinib versus everolimus after first line sunitinib treatment in metastatic renal cell carcinoma. Pathol Oncol Res. 2020;26(4):2201–2207. doi:10.1007/s12253-020-00809-z
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Jonasch E, Michaelson MD, et al. NCCN guidelines insights: kidney cancer, version 2.2020. J Natl Compr Canc Netw. 2019;17(11):1278–1285.
   PubMed Web of Science ®Google Scholar